A Phase 1 interventional study of AT-100 in COVID-19 and Undefined, sponsored by Airway Therapeutics, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Airway Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 1,184th largest by enrollment of the 1,321 interventional ones that give a count, is one of 504 that started in 2021, is one of 178 in phase 1, and was the 841st registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 504 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
Airway Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Airway Therapeutics, Inc. has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if an investigational drug, AT-100, is safe and tolerated by adults who have severe corona virus disease 2019 (COVID-19) or respiratory failure secondary to severe community acquired pneumonia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once daily AT-100 via intratracheal administration for up to 7 doses.
Biological: AT-100
Once daily AT-100 via intratracheal administration for up to 7 doses, if the prior dose level was safe \& tolerated.
Biological: AT-100
Once daily AT-100 via intratracheal administration for up to 7 doses, at the highest safe \& tolerated dose as determined by the prior 2 dosing levels.
Biological: AT-100
reconstituted AT-100 for intratracheal administration
Also known as: (rhSP-D)
Determining the highest-tolerated & safety-tested AT-100 dose
Dose escalation of AT-100 will occur to determine the maximum dose (in mg) that produces no significant Dose Limiting Toxicities or dose-related Adverse Events (AEs).
Time frame: From time of initial AT-100 dosing until the end of the dosing period, up to 7 days
Reduction in mechanical ventilation
Days on mechanical ventilation.
Time frame: From mechanical ventilation initiation up to Day 28
Mortality
Incidence of death.
Time frame: Through study completion, up to Day 90
Ran from Aug 2021 to primary completion in Feb 2023, 18 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zelpultide alfa
Airway Therapeutics, Inc.